Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Liabilities from Discontinued Operations (2018 - 2019)

Plus Therapeutics has reported Liabilities from Discontinued Operations over the past 2 years, most recently at 2102000.0 for Q2 2019.

  • Quarterly Liabilities from Discontinued Operations changed N/A to 2102000.0 in Q2 2019 from the year-ago period, while the trailing twelve-month figure was 2102000.0 through Jun 2019, changed N/A year-over-year, with the annual reading at 245000.0 for FY2018, N/A changed from the prior year.
  • Liabilities from Discontinued Operations was 2102000.0 for Q2 2019 at Plus Therapeutics, up from 245000.0 in the prior quarter.
  • Over five years, Liabilities from Discontinued Operations peaked at 2102000.0 in Q2 2019 and troughed at 245000.0 in Q4 2018.